Hunan Hansen Pharmaceutical Co Ltd (002412) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hunan Hansen Pharmaceutical Co Ltd (002412) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥52.51 Million ≈ $7.68 Million USD) by net assets (CN¥2.26 Billion ≈ $330.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hunan Hansen Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Hunan Hansen Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hunan Hansen Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Hansen Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 002412 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sincere Navigation Corp
TW:2605
|
0.034x |
|
Aura Biosciences Inc
NASDAQ:AURA
|
-0.279x |
|
Patria Investments Ltd
NASDAQ:PAX
|
0.058x |
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
0.057x |
|
Calian Technologies Ltd
TO:CGY
|
0.022x |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
-0.191x |
|
Credit Corp Group Ltd
AU:CCP
|
0.116x |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
0.059x |
Annual Cash Flow Conversion Efficiency for Hunan Hansen Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Hunan Hansen Pharmaceutical Co Ltd from 2007 to 2025. View today's stock price for Hunan Hansen Pharmaceutical Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.38 Billion ≈ $348.40 Million |
CN¥245.38 Million ≈ $35.91 Million |
0.103x | +73.63% |
| 2024-12-31 | CN¥2.20 Billion ≈ $322.42 Million |
CN¥130.78 Million ≈ $19.14 Million |
0.059x | -27.60% |
| 2023-12-31 | CN¥1.96 Billion ≈ $287.25 Million |
CN¥160.95 Million ≈ $23.55 Million |
0.082x | +7.99% |
| 2022-12-31 | CN¥1.89 Billion ≈ $277.17 Million |
CN¥143.81 Million ≈ $21.04 Million |
0.076x | -37.76% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.95 Million |
CN¥212.54 Million ≈ $31.10 Million |
0.122x | +19.95% |
| 2020-12-31 | CN¥1.59 Billion ≈ $233.36 Million |
CN¥162.19 Million ≈ $23.73 Million |
0.102x | -5.76% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.88 Million |
CN¥165.11 Million ≈ $24.16 Million |
0.108x | -32.36% |
| 2018-12-31 | CN¥1.36 Billion ≈ $199.50 Million |
CN¥217.52 Million ≈ $31.83 Million |
0.160x | +81.50% |
| 2017-12-31 | CN¥1.22 Billion ≈ $178.41 Million |
CN¥107.18 Million ≈ $15.68 Million |
0.088x | -31.35% |
| 2016-12-31 | CN¥1.26 Billion ≈ $184.16 Million |
CN¥161.16 Million ≈ $23.58 Million |
0.128x | +152.48% |
| 2015-12-31 | CN¥1.25 Billion ≈ $183.42 Million |
CN¥63.57 Million ≈ $9.30 Million |
0.051x | -31.23% |
| 2014-12-31 | CN¥1.15 Billion ≈ $168.75 Million |
CN¥85.05 Million ≈ $12.44 Million |
0.074x | +7.35% |
| 2013-12-31 | CN¥1.11 Billion ≈ $162.08 Million |
CN¥76.09 Million ≈ $11.13 Million |
0.069x | -33.85% |
| 2012-12-31 | CN¥965.11 Million ≈ $141.23 Million |
CN¥100.23 Million ≈ $14.67 Million |
0.104x | +70.44% |
| 2011-12-31 | CN¥883.65 Million ≈ $129.31 Million |
CN¥53.84 Million ≈ $7.88 Million |
0.061x | +157.83% |
| 2010-12-31 | CN¥898.82 Million ≈ $131.53 Million |
CN¥21.24 Million ≈ $3.11 Million |
0.024x | -89.66% |
| 2009-12-31 | CN¥179.51 Million ≈ $26.27 Million |
CN¥41.02 Million ≈ $6.00 Million |
0.228x | -12.30% |
| 2008-12-31 | CN¥130.26 Million ≈ $19.06 Million |
CN¥33.94 Million ≈ $4.97 Million |
0.261x | -39.43% |
| 2007-12-31 | CN¥87.77 Million ≈ $12.84 Million |
CN¥37.75 Million ≈ $5.52 Million |
0.430x | -- |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more